BACKGROUND: There is interest in different treatment strategies, including deintensification in good prognosis human papillomavirus-positive (HPV(+)) oropharyngeal squamous cell carcinoma (SCC). We reviewed our experience with weekly cisplatin in low-risk, locoregionally advanced HPV(+) oropharyngeal SCC since late 2009. METHODS: Data from patients with low-risk HPV(+) oropharyngeal SCC treated with weekly cisplatin (40 mg/m(2) ) and 70 Gy radiotherapy were collected. Low risk was defined as stage III to IV oropharyngeal SCC excluding T1-2N1, T4 or N3 disease, or N2b to N2c disease in patients with >10 pack-year smoking history. RESULTS: Of 31 patients, the median age was 56 years (range, 41-69 years). All patients completed 70 Gy radiotherapy within 51 days and 84% completed at least 5 cycles of cisplatin. Grade 3 mucositis occurred in 22 patients (71%) and grade 3 febrile neutropenia in 6 patients (19%). No patients required enteral feeding at 12 months. The median follow-up was 30 months (range, 21-57 months) with no recurrences or deaths. CONCLUSION: Concurrent weekly cisplatin is relatively well-tolerated and associated with excellent disease control in low-risk, locoregionally advanced HPV(+) oropharyngeal SCC.
BACKGROUND: There is interest in different treatment strategies, including deintensification in good prognosis human papillomavirus-positive (HPV(+)) oropharyngeal squamous cell carcinoma (SCC). We reviewed our experience with weekly cisplatin in low-risk, locoregionally advanced HPV(+) oropharyngeal SCC since late 2009. METHODS: Data from patients with low-risk HPV(+) oropharyngeal SCC treated with weekly cisplatin (40 mg/m(2) ) and 70 Gy radiotherapy were collected. Low risk was defined as stage III to IV oropharyngeal SCC excluding T1-2N1, T4 or N3 disease, or N2b to N2c disease in patients with >10 pack-year smoking history. RESULTS: Of 31 patients, the median age was 56 years (range, 41-69 years). All patients completed 70 Gy radiotherapy within 51 days and 84% completed at least 5 cycles of cisplatin. Grade 3 mucositis occurred in 22 patients (71%) and grade 3 febrile neutropenia in 6 patients (19%). No patients required enteral feeding at 12 months. The median follow-up was 30 months (range, 21-57 months) with no recurrences or deaths. CONCLUSION: Concurrent weekly cisplatin is relatively well-tolerated and associated with excellent disease control in low-risk, locoregionally advanced HPV(+) oropharyngeal SCC.
Authors: James M Melotek; Benjamin T Cooper; Matthew Koshy; Joshua S Silverman; Michael T Spiotto Journal: J Otolaryngol Head Neck Surg Date: 2016-11-24
Authors: Vlad C Sandulache; Yunyun Chen; Lei Feng; William N William; Heath D Skinner; Jeffrey N Myers; Raymond E Meyn; Jinzhong Li; Ainiwaer Mijiti; James A Bankson; Clifton D Fuller; Marina Y Konopleva; Stephen Y Lai Journal: Oncotarget Date: 2017-03-14
Authors: Eric J Di Gravio; Pencilla Lang; Hugh Andrew Jinwook Kim; Tricia Chinnery; Neil Mundi; S Danielle MacNeil; Adrian Mendez; John Yoo; Kevin Fung; Joe S Mymryk; John W Barrett; Nancy Read; Varagur Venkatesan; Sara Kuruvilla; Lucas C Mendez; Eric Winquist; Sylvia Mitchell; Sarah A Mattonen; Anthony C Nichols; David A Palma Journal: Radiat Oncol Date: 2020-11-10 Impact factor: 3.481
Authors: Piotr Kędzierawski; Anna Huruk-Kuchinka; Agnieszka Radowicz-Chil; Ryszard Mężyk; Zdzisława Rugała; Jacek Sadowski Journal: Arch Med Sci Date: 2020-09-23 Impact factor: 3.318